NYSE:GEN - Genesis Healthcare Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.57
  • Forecasted Upside: 9.93 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.52
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Genesis Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GEN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.57
▲ +9.93% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Genesis Healthcare in the last 3 months. The average price target is $0.57, with a high forecast of $0.57 and a low forecast of $0.57. The average price target represents a 9.93% upside from the last price of $0.52.
Hold
The current consensus among 1 investment analysts is to hold stock in Genesis Healthcare. This rating has held steady since November 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/12/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2020

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2020Credit Suisse GroupLower Price TargetNeutral$0.75 ➝ $0.57Medium
i
2/4/2019Credit Suisse GroupReiterated RatingHoldLow
i
11/28/2018Stifel NicolausUpgradeHold ➝ Buy$2.00 ➝ $2.50High
i
11/7/2018Cantor FitzgeraldReiterated RatingBuy$7.00High
i
10/16/2018Credit Suisse GroupInitiated CoverageNeutral$1.75Low
i
10/3/2018Cantor FitzgeraldReiterated RatingBuy$7.00Low
i
8/7/2018Cantor FitzgeraldReiterated RatingBuy$7.00High
i
4/24/2018Stifel NicolausSet Price TargetHold$2.00Medium
i
Rating by Chad Vanacore at Stifel Nicolaus
3/19/2018StephensReiterated RatingHold$2.00High
i
9/13/2017Royal Bank of CanadaReiterated RatingHold$2.00Low
i
7/5/2017Cantor FitzgeraldInitiated CoverageOverweightHigh
i
1/3/2017Royal Bank of CanadaReiterated RatingHold$3.50N/A
i
11/21/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$3.00 ➝ $3.50N/A
i
9/19/2016Bank of AmericaSet Price TargetSell$1.80N/A
i
Rating by joanna gajuk at Bank of America Co.
8/22/2016UBS GroupReiterated RatingSellN/A
i
5/16/2016Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
i
5/16/2016Royal Bank of CanadaLower Price TargetOutperform$5.00 ➝ $3.00N/A
i
5/11/2016StephensDowngradeOverweight ➝ HoldN/A
i
2/8/2016UBS GroupDowngradeNeutral ➝ Sell$1.50N/A
i
Rating by A.J. Rice at UBS Group AG
1/26/2016140166Lower Price TargetNeutral$5.50 ➝ $2.75N/A
i
1/26/2016Royal Bank of CanadaLower Price TargetOutperform$10.00 ➝ $5.00N/A
i
1/25/2016Bank of AmericaDowngradeBuy ➝ Neutral$2.50N/A
i
(Data available from 12/3/2015 forward)
Genesis Healthcare logo
Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of April 23, 2020, it provided inpatient services through a network of approximately 400 skilled nursing facilities and assisted/senior living communities in 25 states; and supplied rehabilitation and respiratory therapy to approximately 1,200 healthcare locations in 44 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.
Read More

Today's Range

Now: $0.52
$0.50
$0.52

50 Day Range

MA: $0.48
$0.42
$0.53

52 Week Range

Now: $0.52
$0.40
$1.86

Volume

735,260 shs

Average Volume

866,142 shs

Market Capitalization

$86.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7